Compare Sea Limited (SE) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sea Limited vs Viatris Inc — how do they compare? Sea Limited trades at $94.4 (market cap $56.89B), while Viatris Inc trades at $17.49 (market cap $20.03B). The key difference: Sea Limited is far larger — about 2.8× Viatris Inc's market cap, and Viatris Inc pays a 2.75% dividend while Sea Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sea Limited for 102 Days and Viatris Inc for 57 Days on average.
| SE | VTRS | |
|---|---|---|
Market Cap | $56.89B | $20.03B |
Volume | 5,359,457 | 14,109,977 |
Sector | Consumer Cyclical | Health |
52-Week High | $188.00 | $18.27 |
52-Week Low | $78.16 | $9.74 |
Typical Hold Time | 102 Days | 57 Days |
Enterprise Value | $51.92B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sea Limited (SE) trades at $94.66, down 1.94% on the day, with technical indicators showing bearish momentum despite oversold RSI readings. The company demonstrates strong fundamental progress with revenue growing from $12.4B in 2022 to $22.9B in 2025 and achieving profitability, though recent Q4 2025 earnings missed expectations. Analyst sentiment remains overwhelmingly positive with 31 buy ratings and a $153.67 consensus price target, representing significant upside potential from current levels.
Sea presents a compelling growth story with expanding profitability and strong e-commerce momentum, though execution risks and competitive pressures persist. The stock's current valuation at 36.55x P/E reflects growth expectations, while technical weakness suggests potential near-term consolidation. Institutional confidence remains high despite recent insider selling activity.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
